Trials / Terminated
TerminatedNCT02596477
Evaluation of Vepoloxamer in Chronic Heart Failure
A Phase 2 Randomized, Double-Blind, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects With Chronic Heart Failure
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Mast Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether vepoloxamer can provide a blood chemical marker and functional benefit to damaged heart muscle cells. This will be evaluated by measurement of blood-based laboratory markers, exercise tolerance, and echocardiograms. In addition, the safety and blood levels of vepoloxamer in subjects with chronic heart failure will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vepoloxamer | |
| OTHER | 5% dextrose in water |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2016-10-01
- First posted
- 2015-11-04
- Last updated
- 2016-10-28
Locations
4 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT02596477. Inclusion in this directory is not an endorsement.